MARKET

OSTX

OSTX

OS THERAPIES INCORPORATED
AMEX
1.600
+0.060
+3.90%
After Hours: 1.640 +0.04 +2.50% 19:48 12/18 EST
OPEN
1.610
PREV CLOSE
1.540
HIGH
1.680
LOW
1.597
VOLUME
328.42K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
1.120
MARKET CAP
56.34M
P/E (TTM)
-1.6338
1D
5D
1M
3M
1Y
5Y
1D
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
TipRanks · 2d ago
Lake Street Sticks to Their Buy Rating for OS Therapies Incorporated (OSTX)
TipRanks · 2d ago
OS Therapies Is Maintained at Buy by D. Boral Capital
Dow Jones · 3d ago
OS Therapies Price Target Maintained With a $20.00/Share by D. Boral Capital
Dow Jones · 3d ago
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
Benzinga · 3d ago
OS Therapies Held An FDA Type C Meeting Regarding The Phase 2B Trial Of OST-HER2 To Prevent Or Delay Recurrent, Fully-resected, Pulmonary Metastatic Osteosarcoma, And Intends To File BLA By The End January 2026
Benzinga · 3d ago
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Newsfile · 3d ago
Weekly Report: what happened at OSTX last week (1208-1212)?
Weekly Report · 3d ago
More
About OSTX
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Webull offers OS Therapies Inc stock information, including AMEX: OSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OSTX stock methods without spending real money on the virtual paper trading platform.